These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 11451620)
1. The influence of hormone replacement therapy on skin ageing: a pilot study. Sator PG; Schmidt JB; Sator MO; Huber JC; Hönigsmann H Maturitas; 2001 Jul; 39(1):43-55. PubMed ID: 11451620 [TBL] [Abstract][Full Text] [Related]
2. Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study. Holzer G; Riegler E; Hönigsmann H; Farokhnia S; Schmidt JB Br J Dermatol; 2005 Sep; 153(3):626-34. PubMed ID: 16120154 [TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized, double-blind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women. Sator PG; Sator MO; Schmidt JB; Nahavandi H; Radakovic S; Huber JC; Hönigsmann H Climacteric; 2007 Aug; 10(4):320-34. PubMed ID: 17653959 [TBL] [Abstract][Full Text] [Related]
4. Circulating dehydroepiandrosterone-sulphate decreases even with a slight change in oestradiol. Matsui S; Yasui T; Kasai K; Yoshida K; Kato T; Uemura H; Kuwahara A; Matsuzaki T; Irahara M J Obstet Gynaecol; 2018 Feb; 38(2):231-235. PubMed ID: 28903616 [TBL] [Abstract][Full Text] [Related]
5. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia. Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of oestrogens, progesterone, follicle-stimulating hormone and sex-hormone-binding globulin during simultaneous vaginal administration of 17 beta-oestradiol and progesterone in the pre- and post-menopause. Carlström K; Pschera H; Lunell NO Maturitas; 1988 Dec; 10(4):307-16. PubMed ID: 3147360 [TBL] [Abstract][Full Text] [Related]
7. [Measurement of skin thickness by high-frequency ultrasound to objectify the effects of hormone replacement therapy in the perimenopause]. Sator PG; Sator MO; Schmidt JB; Huber JC; Hönigsmann H Ultraschall Med; 2001 Oct; 22(5):219-24. PubMed ID: 11607890 [TBL] [Abstract][Full Text] [Related]
8. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women. Seed M; Sands RH; McLaren M; Kirk G; Darko D Fam Pract; 2000 Dec; 17(6):497-507. PubMed ID: 11120722 [TBL] [Abstract][Full Text] [Related]
9. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559 [TBL] [Abstract][Full Text] [Related]
10. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. de Ziegler D; Ferriani R; Moraes LA; Bulletti C Hum Reprod; 2000 Jun; 15 Suppl 1():149-58. PubMed ID: 10928426 [TBL] [Abstract][Full Text] [Related]
11. An intrauterine progesterone contraceptive system (52 mg) used in pre- and peri-menopausal patients with endometrial hyperplasia. Volpe A; Botticelli A; Abrate M; Dalla Vecchia E; Mantovani M; Carani C; Grasso A; Mazza V; Di Renzo GC Maturitas; 1982 Apr; 4(1):73-9. PubMed ID: 6285154 [TBL] [Abstract][Full Text] [Related]